Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Introgen files for Chapter 11

This article was originally published in Scrip

Executive Summary

Introgen Therapeuticshas filed Chapter 11 petitions in the US Bankruptcy Court to enable the company to implement its reorganisation strategy. Introgen cut its staff from 45 to 15 employees to focus on the expansion of its manufacturing and service subsidiary Introgen Technical Serviceslast month. The company expects that its non-manufacturing operations will be significantly reduced and will mainly support achieving regulatory approval for its gene therapy drug Advexin. The FDA issued a refusal to file decision on Advexin in September saying that the application was not sufficiently complete (Scrip Online, September 5th, 2008). Since then, the company's share price has plummeted and in October it received a warning letter from the Nasdaq saying that its common stock had been below the required $1.00 minimum bid price for the past 30 days. Introgen is seeking approval to market its therapeutic portfolio and other assets to prospective buyers and expects to emerge from Chapter 11 next year.

Topics

UsernamePublicRestriction

Register

SC007946

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel